16.85
0.22 (1.32%)
| Previous Close | 16.63 |
| Open | 16.70 |
| Volume | 914,166 |
| Avg. Volume (3M) | 898,773 |
| Market Cap | 834,514,816 |
| Price / Earnings (Forward) | 625.00 |
| Price / Sales | 2.98 |
| Price / Book | 2.39 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -25.46% |
| Operating Margin (TTM) | -81.43% |
| Diluted EPS (TTM) | -1.44 |
| Quarterly Revenue Growth (YOY) | -44.90% |
| Quarterly Earnings Growth (YOY) | 107.20% |
| Total Debt/Equity (MRQ) | 10.48% |
| Current Ratio (MRQ) | 4.78 |
| Operating Cash Flow (TTM) | -11.69 M |
| Levered Free Cash Flow (TTM) | 10.73 M |
| Return on Assets (TTM) | -5.90% |
| Return on Equity (TTM) | -19.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | STAAR Surgical Company | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 0.64% |
| % Held by Institutions | 109.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Resona Asset Management Co.,Ltd. | 31 Mar 2025 | 2,169,618 |
| Yunqi Capital Ltd | 31 Mar 2025 | 1,937,589 |
| American Capital Management Inc | 31 Mar 2025 | 1,010,164 |
| Jupiter Asset Management Ltd | 31 Mar 2025 | 566,079 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Canaccord Genuity, 18.69%) | Hold |
| Median | 18.50 (9.79%) | |
| Low | 17.00 (Wells Fargo, 0.89%) | Hold |
| Average | 18.50 (9.79%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 17.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 27 May 2025 | 20.00 (18.69%) | Hold | 18.92 |
| 08 May 2025 | 20.00 (18.69%) | Hold | 19.53 | |
| Wells Fargo | 21 Apr 2025 | 17.00 (0.89%) | Hold | 16.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Jun 2025 | Announcement | STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors |
| 22 May 2025 | Announcement | STAAR Surgical Announces Participation in Upcoming Investor Conferences |
| 16 May 2025 | Announcement | STAAR Surgical Announces $30 Million Share Repurchase Authorization |
| 07 May 2025 | Announcement | STAAR Surgical Reports First Quarter 2025 Results |
| 24 Apr 2025 | Announcement | STAAR Surgical Announces Changes to Board of Directors |
| 23 Apr 2025 | Announcement | STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |